CTXR Stock Analysis: Buy, Sell, or Hold?
CTXR - Citius Pharmaceuticals Inc. Common
$0.57
-0.03 (-5.63%)
▼
5d:
+5.41%
30d:
-4.76%
90d:
-31.85%
BUY
HIGH Confidence
Analysis Updated: Jul 2, 2026 12:00 AM ET
Earnings: Aug 11, 2026
Get Alerted When CTXR Hits Your Target Price
Join 10,000+ traders who never miss a move
You're in! Check your email to confirm and set your target price.
100% Free
No spam, ever
Unsubscribe anytime
Interactive Price Chart (1 Month)
Loading chart...
Loading historical data...
Bottom Line:
✅ BUY SIGNAL: CTXR shows strong fundamentals and good volume confirmation. Solid entry point despite fair pricing.
✅ BUY SIGNAL: CTXR shows strong fundamentals and good volume confirmation. Solid entry point despite fair pricing.
In-depth Analysis How we analyze
Valuation Analysis: CTXR is currently trading at $0.57, which is considered fair relative to its 30-day fair value range of $0.54 to $0.63. From a valuation perspective, the stock is trading at a discount (Forward PE: -0.7) compared to its historical average (0.3). At these levels, the market is pricing in 0% annual earnings growth. This growth rate appears achievable given the company's track record, suggesting the valuation is rational.
Technical Outlook: Technically, CTXR is in a downtrend. Immediate support is located at $0.54, while resistance sits at $0.68. Short-term momentum is weak, with the stock down 5.6% recently.
Market Sentiment: CTXR has a strong technical setup (60/100), with favorable trendlines, momentum, and price action for short-term traders. In the options market, Implied Volatility is low (29th percentile), suggesting options premiums are relatively cheap. This makes it an attractive time for long options strategies if you have a directional bias. Wall Street analysts see significant upside, with an average price target of $4.00 (+596.1%). Combining these factors, the current setup offers a favorable risk/reward ratio for buyers.
Technical Outlook: Technically, CTXR is in a downtrend. Immediate support is located at $0.54, while resistance sits at $0.68. Short-term momentum is weak, with the stock down 5.6% recently.
Market Sentiment: CTXR has a strong technical setup (60/100), with favorable trendlines, momentum, and price action for short-term traders. In the options market, Implied Volatility is low (29th percentile), suggesting options premiums are relatively cheap. This makes it an attractive time for long options strategies if you have a directional bias. Wall Street analysts see significant upside, with an average price target of $4.00 (+596.1%). Combining these factors, the current setup offers a favorable risk/reward ratio for buyers.
Quick Decision Summary
Current Position
FAIR
Historical Trading Range
$0.54 -
$0.63
Company Quality Score
50/100
(HOLD)
Options IV Signal
29th percentile
(LOW)
Volume Confirmation
HIGH
Confidence Score
86.5%
All Signals
- NEUTRAL: Price in fair range
- BULLISH: Options cheap (IV 29th percentile)
- BULLISH: Strong technical setup (60/100)
- BULLISH: High volume confirmation
- BEARISH: Downward momentum (-5.6%)
- BULLISH: Trading 596.1% below Wall St target ($4.00)
- BULLISH: Market expects only 0% annual growth - appears undervalued
Trading Range Analysis
30-Day Trading Range
$0.54 -
$0.63
Current vs Trading Range
FAIR
Expected Move (7 Days)
±$0.21
(35.7%)
Support & Resistance Levels
Support Level
$0.54
Resistance Level
$0.68
Current Trend
Downtrend
Technical data as of
Jun 12, 2026
Fundamental Context
Forward P/E (Next Year Est.)
-0.71
Wall Street Target
$4.00
(+596.1%)
PE vs Historical
-0.7 vs 0.3
CHEAP
Share & Embed Analysis
Last updated: July 02, 2026 10:54 PM ET
Data refreshes hourly during market hours. Next update: 11:53 PM
Data refreshes hourly during market hours. Next update: 11:53 PM
🔥 Top Stocks Breaking Out Now
| Ticker | Score | Recommendation | Change % |
|---|
Technical Signals Check
Is CTXR showing a specific setup today?
Insider Activity (6 Months)
0
Buys
0
Sells
0
Net
NEUTRAL
Top Rated Biotechnology Stocks
Top-rated stocks in Biotechnology by analyst ratings.
| Stock | Analyst Consensus | Analyst Target | Tradestie Score |
|---|---|---|---|
|
JAZZ
Jazz Pharmaceuticals PLC |
STRONG BUY
18 analysts |
$257 | 61 BUY |
|
BEAM
Beam Therapeutics Inc |
STRONG BUY
17 analysts |
$51 | 62 BUY |
|
TVTX
Travere Therapeutics Inc |
STRONG BUY
15 analysts |
$58 | 61 BUY |
|
DNTH
Dianthus Therapeutics In… |
STRONG BUY
12 analysts |
$128 | 57 HOLD |
|
ARWR
Arrowhead Pharmaceutical… |
STRONG BUY
13 analysts |
$89 | 64 BUY |
